Digital diabetes management provider, GlucoMe, today announced that its new Decision Support System (DSS) has received a CE Mark in Europe.
DSS is a reliable, algorithm-based, clinical decision support software that assists physicians to ensure optimal oral drug intensification for patients with Type 2 Diabetes.
Diabetes is a progressive disorder and despite guidelines mandating drug intensification within 3-6 months of initial treatment, it is often delayed.
This can lead to poor diabetes control and associated health complications. GlucoMe’s DSS uses a proprietary advanced algorithm that enables real-time analysis of patient-specific data to provide physicians with treatment recommendations.
The algorithm is 100% compliant with internationally-recognized medication guidelines (ADA and EASD guidelines consensus, 2018).
“Receiving the CE mark is a major leap forward to realizing our vision of providing a smart, end-to-end digital platform that enables efficient and comprehensive diabetes management, said Yiftah Ben-Aharon, GlucoMe’s CEO. “Health care providers and physicians now have a valuable and practical tool that empowers their decision making to better personalize Type 2 diabetes patient treatment plans.”
Aharon added using the DSS will enable better diabetes control by ensuring each patient receives timely treatment, as well as reduce associated costs from diabetes complications.
GlucoMe’s solution helps bridge the gap in upholding proper drug intensification timelines, empowering physicians to personalize management of Type 2 diabetes and improve care.
GlucoMe’s cloud-based/SaaS solution achieved similar medication recommendations in pilot studies to that of endocrinologists and exceeded that of primary caregivers.
The algorithm generated medication recommendations that were 98% in agreement with endocrinologists versus 82% agreement with GPs.
The GlucoMe DSS can be either integrated into a third party EHR – EMR software or can be directly operated from GlucoMe’s Digital Diabetes Management platform.
Featured image: Decision Support System (DSS) assists physicians and health care organizations to ensure optimal oral drug intensification for Type 2 Diabetes patients. (PRNewsfoto/GlucoMe).